Processing

Please wait...

Settings

Settings

Goto Application

1. CA2653787 - COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
CLAIMS:
1. Use of a composition comprising ethyl icosapentate as its effective component and at least one pharmaceutically acceptable carrier, in combination with a 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, for primary prevention of a cardiovascular event where hypercholesterolemia, a serum triglyceride (TG) value of at least 150 mg/dL, and a low HDL cholesterolemia defined by serum HDL-C value of less than 40 mg/dL, exist.
2. The use of the composition according to claim 1, wherein at least one risk factor selected from the group consisting of (1) obesity, (2) hypertension or prehypertension, and (3) diabetes, prediabetes, or abnormal glucose tolerance, further exists.
3. The use of the composition according to claim 1 or 2, wherein (1) obesity, (2) hypertension or prehypertension, and (3) diabetes, prediabetes, or abnormal glucose tolerance, further exists.
4. The use of the composition according to any one of claims 1 .to 3, wherein the obesity is defined by a body mass index (BMI) of at least 25; the hypertension or the prehypertension is defined by a systolic blood pressure (SBP)
of at least 140 mmHg or a diastolic blood pressure (DBP) of at least 90 mmHg; the diabetes, the prediabetes, or the abnormal glucose tolerance is defined by a fasting blood glucose (FBS) of at least 126 mg/dL or a haemoglobin A1c (HbA1c) of at least 6.5%.
5. The use of the composition according to any one of claims 1 to 4, wherein the content of the ethyl icosapentate is at least 96.5% by weight in relation to the total content of fatty acid and derivatives thereof.
6. The use of the composition according to any one of claims 1 to 5, wherein the composition is for oral delivery at an ethyl icosapentate dose of 0.3 g/day to 6 g/day.
7. The use of the composition according to any one of claims 1 to 6, wherein the composition is for oral delivery at an ethyl icosapentate dose of 1.8 g/day to 2.7 g/day.
8. The use of the composition according to any one of claims 1 to 7, wherein the hypercholesterolemia patient is a male patient.
9. The use of the composition according to any one of claims 1 to 8, wherein the composition further comprises a 3hydroxy-3-methylglutaryl coenzyme A reductase inhibitor as its effective component.
10. Use of a composition comprising ethyl icosapentate as its effective component and at least one pharmaceutically acceptable carrier, in combination with a 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, for primary prevention of a cardiovascular event where
hypercholesterolemia, and at least two risk factors selected from the group consisting of (1) obesity, (2) hypertension or prehypertension, (3) diabetes, prediabetes, or abnormal glucose tolerance, and (4) hypertriglyceridemia and/or low HDL cholesterolemia, exist, and wherein the composition is for treatment of a male patient.
11. The use of the composition according to claim 10, wherein the obesity is defined by a body mass index (BMI) of at least 25; the hypertension or the prehypertension is defined by a systolic blood pressure (SBP) of at least 140 mmHg or a diastolic blood pressure (DBP) of at least 90 mmHg; the diabetes, the prediabetes, or the abnormal glucose tolerance is defined by a fasting blood glucose (FBS) of at least 126 mg/dL or a haemoglobin A1c (HbA1c) of at least 6.5%; and the hypertriglyceridemia and/or low HDL cholesterolemia is defined by triglycerides (TG) of at least 150 mg/dL and/or a HDL cholesterol of less than 40 mg/dL.
12. The use of the composition according to claim 10 or 11, wherein the male hypercholesterolemia patient has a serum TG/HDL-C ratio of at least 3.75.
13. The use of the composition according to any one of claims 10 to 12, wherein the content of the ethyl icosapentate is at least 96.5% by weight in relation to the total content of fatty acid and derivatives thereof.
14. The use of the composition according to any one of claims 10 to 13, wherein the composition is for oral delivery at an ethyl icosapentate dose of 0.3 g/day to 6 g/day.
15. The use of the composition according to any one of claims 10 to 14, wherein the composition is for oral delivery at an ethyl icosapentate dose of 1.8 g/day to 3.6 g/day.
16. The use of the composition according to any one of claims 10 to 15, wherein the composition further comprises a 3hydroxy-3-methylglutaryl coenzyme A reductase inhibitor as its effective component.